drugset / Trial / NCT05337137
A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in participants with untreated advanced/metastatic hepatocellular carcinoma (HCC).
Timeline
- Start
- 2022-05-05
- Primary completion
- 2025-07-05
- Completion
- 2025-11-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Relatlimab | Monoclonal antibody | — | — |
| Background | Bevacizumab | Monoclonal antibody | — | — |
| Background | Nivolumab | Monoclonal antibody | — | — |